2026-06-25

Silver volume spike - 6.3× the 20-day average (573 vs 90 avg)

Platinum volume spike - 5.1× the 20-day average (61 vs 11 avg)

OSINT: US Supreme Court Blocks Roundup Cancer Lawsuits, Shields Bayer

Cocoa bull 6.7% vs prior close ($4,902.00 → $5,230.00)

Cotton bull 6.3% vs prior close ($72.09 → $76.61)

OSINT: US Investor Confidence Falls to 25%, Down from 34% Last Quarter

OSINT: Saudi Arabia oil output update draws market attention

OSINT: Iran-linked wallets shift $3.84B via CoinEx, including Revolutionary Guard funds

Oil -5.12%: significant decline on the session

Soybeans bull 4.4% vs prior close ($1,108.75 → $1,157.50)

Cocoa volume spike - 2.2× the 20-day average (28,502 vs 13,134 avg)

Corn bull 4.2% vs prior close ($407.00 → $424.25)

Sugar No. 11 bull 5.2% vs prior close ($13.42 → $14.12)

Coffee bear 5.1% vs prior close ($291.55 → $276.75)

Oil +1.61%: significant gain on the session

Gold +1.48%: significant gain on the session

OSINT: Congress Introduces AI Data Center Moratorium Bill

Oil +1.68%: significant gain on the session

Gold +1.01%: significant gain on the session

Oil -1.01%: significant decline on the session

GOLD RSI 29.5 - oversold (crossed below 30)

Copper bull 3.0% vs prior close ($5.94 → $6.12)

Ukraine Black Sea Belt: crop water stress detected (1.5σ above baseline) - potential ZW=F supply pressure

Phase 3 trial terminated early - JOHNSON A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Pati

Phase 3 trial terminated early - BIOGEN A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants Wit

Phase 3 trial terminated early - AMGEN Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects

Phase 3 trial terminated early - AMGEN Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or M

Phase 3 trial terminated early - Merck Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis

Phase 3 trial terminated early - Merck Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppress

Phase 3 trial terminated early - Merck MK0767 and Sulfonylurea Combination Study (0767-027)

Phase 3 trial terminated early - PFIZER Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infect

Phase 3 trial terminated early - PFIZER Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized A

Phase 3 trial terminated early - PFIZER An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Toler

Phase 3 trial terminated early - PFIZER Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atr

Phase 3 trial terminated early - PFIZER A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In P

Phase 3 trial terminated early - PFIZER Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For

Phase 3 trial terminated early - PFIZER Phase III Acute Coronary Syndrome

Phase 3 trial terminated early - ABBOTT Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients

Phase 3 trial terminated early - ABBOTT Study of Trilipix Effects on Lipids and Arteries

Phase 3 trial terminated early - GILEAD Roll Over Study to Provide Idelalisib to Participants Previously Treated With th

Phase 3 trial terminated early - GILEAD ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monothe

Phase 3 trial terminated early - GILEAD Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to N

Phase 3 trial terminated early - GILEAD Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously

Phase 3 trial terminated early - GILEAD Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of E

Activist 13D filing - engage in discussions

CVS HEALTH Corp search volume spiked +88 pts - unusual interest

Sanofi search volume spiked +37 pts - unusual interest

Q1-2026: Beat consensus by 14.3% - EPS $1.16 vs $1.015 estimate

Q1-2012: Beat consensus by 22.8% - EPS $3.1 vs $2.525 estimate

Q3-2020: Missed consensus by 31.0% - EPS $4.6 vs $6.666 estimate

Q4-2011: Beat consensus by 14.0% - EPS $3.8 vs $3.333 estimate

Q2-2012: Beat consensus by 132.7% - EPS $9.4 vs $4.04 estimate

Q4-2019: Beat consensus by 37.0% - EPS $-192000 vs $-304616 estimate

Q1-2026: Beat consensus by 21.6% - EPS $-0.16 vs $-0.204 estimate

Q2-2025: Beat consensus by 27.5% - EPS $-0.37 vs $-0.51 estimate

Q2-2025: Beat consensus by 14.7% - EPS $0.75 vs $0.654 estimate

Q3-2021: Missed consensus by 178.6% - EPS $-40.5 vs $-14.535 estimate

Q2-2022: Missed consensus by 35.6% - EPS $-8.3 vs $-6.12 estimate

Q4-2021: Missed consensus by 5.0% - EPS $-22.5 vs $-21.42 estimate

Q4-2025: Missed consensus by 51.3% - EPS $-1.38 vs $-0.912 estimate

Q3-2025: Beat consensus by 14.6% - EPS $0.59 vs $0.515 estimate

Q2-2025: Missed consensus by 31.9% - EPS $0.55 vs $0.808 estimate

Q3-2025: Beat consensus by 65.8% - EPS $0.62 vs $0.374 estimate

Q2-2024: Missed consensus by 82.4% - EPS $-0.93 vs $-0.51 estimate

Q1-2024: Beat consensus by 36.3% - EPS $-0.39 vs $-0.612 estimate

Q4-2025: Beat consensus by 7.8% - EPS $0.44 vs $0.408 estimate

Q1-2026: Missed consensus by 15.4% - EPS $-0.09 vs $-0.078 estimate

Q2-2025: Beat consensus by 12.6% - EPS $-0.09 vs $-0.103 estimate

Q3-2025: Beat consensus by 27.0% - EPS $8.14 vs $6.409 estimate

Q3-2025: Beat consensus by 27.5% - EPS $0.13 vs $0.102 estimate

Q2-2025: Missed consensus by 46.7% - EPS $-46.3 vs $-31.569 estimate

Q3-2025: Beat consensus by 7.4% - EPS $-7.6 vs $-8.211 estimate

Q1-2026: Beat consensus by 40.1% - EPS $-2.75 vs $-4.59 estimate

Q1-2025: Missed consensus by 120.6% - EPS $-45 vs $-20.4 estimate

Q1-2026: Beat consensus by 6.5% - EPS $1.18 vs $1.108 estimate

Q3-2026: Beat consensus by 56.9% - EPS $0.08 vs $0.051 estimate

Q4-2026: Beat consensus by 56.9% - EPS $0.36 vs $0.2295 estimate

Q4-2025: Missed consensus by 71.7% - EPS $0.13 vs $0.459 estimate

Q4-2025: Beat consensus by 137.4% - EPS $0.07 vs $-0.187 estimate

Q4-2025: Beat consensus by 10.3% - EPS $0.8 vs $0.725 estimate

Q4-2025: Beat consensus by 6.0% - EPS $3.85 vs $3.6314 estimate

Q3-2025: Missed consensus by 16.7% - EPS $0.08 vs $0.096 estimate

Q1-2026: Missed consensus by 429.9% - EPS $-6.77 vs $-1.2776 estimate

Q3-2011: Beat consensus by 6.4% - EPS $0.86 vs $0.808 estimate

Q1-2026: Beat consensus by 26.0% - EPS $1.4 vs $1.111 estimate

Q1-2026: Beat consensus by 30.2% - EPS $0.44 vs $0.338 estimate

Q1-2026: Beat consensus by 5.5% - EPS $0.71 vs $0.6732 estimate

Q3-2025: Beat consensus by 34.7% - EPS $-0.85 vs $-1.302 estimate

Q2-2026: Beat consensus by 7.7% - EPS $2.56 vs $2.376 estimate

Q2-2025: Beat consensus by 8.8% - EPS $0.69 vs $0.634 estimate

Q1-2026: Beat consensus by 12.2% - EPS $0.47 vs $0.419 estimate

Q1-2026: Beat consensus by 6.8% - EPS $0.89 vs $0.833 estimate

Q1-2025: Beat consensus by 8.1% - EPS $-0.15 vs $-0.1632 estimate

Q2-2025: Missed consensus by 98.3% - EPS $0.01 vs $0.602 estimate

Q3-2025: Missed consensus by 5.0% - EPS $1.918 vs $2.02 estimate

Q2-2025: Missed consensus by 43.3% - EPS $1.03 vs $1.816 estimate

Q4-2024: Missed consensus by 250.4% - EPS $-3.95 vs $2.626 estimate

Q2-2025: Beat consensus by 30.8% - EPS $-0.12 vs $-0.1734 estimate

Q3-2025: Beat consensus by 8.7% - EPS $1.89 vs $1.738 estimate

Q1-2026: Beat consensus by 5.5% - EPS $2.5 vs $2.369 estimate

Q1-2026: Missed consensus by 5.8% - EPS $1.04 vs $1.104 estimate

Q2-2025: Beat consensus by 6.9% - EPS $1.46 vs $1.366 estimate

Q2-2026: Beat consensus by 17.3% - EPS $0.41 vs $0.3496 estimate

Q4-2025: Beat consensus by 97.9% - EPS $-0.03 vs $-1.428 estimate

Q1-2026: Beat consensus by 15.3% - EPS $-0.76 vs $-0.8976 estimate

Q1-2025: Beat consensus by 91.1% - EPS $-7.36 vs $-82.62 estimate

Q2-2025: Missed consensus by 96.9% - EPS $1.87 vs $61.2 estimate

AAPL RSI 23.1 - oversold (crossed below 30)

MORGAN STANLEY search volume spiked +46 pts - unusual interest

OSINT: Apple price hikes hit iPad, Mac, shares tumble 5%

Callaway Golf Co search volume spiked +100 pts - unusual interest

CVS HEALTH Corp search volume spiked +88 pts - unusual interest

OSINT: Congress Introduces AI Data Center Moratorium Bill

Sanofi search volume spiked +37 pts - unusual interest

OSINT: US Investor Confidence Falls to 25%, Down from 34% Last Quarter

AAPL RSI 27.1 - oversold (crossed below 30)

MORGAN STANLEY search volume spiked +46 pts - unusual interest

Callaway Golf Co search volume spiked +100 pts - unusual interest

CVS HEALTH Corp search volume spiked +88 pts - unusual interest

MORGAN STANLEY search volume spiked +46 pts - unusual interest

Callaway Golf Co search volume spiked +100 pts - unusual interest

OSINT: Meta speeds AI rollout, halves human content moderation workload

OSINT: Google loses two senior AI researchers to Anthropic, raising AI talent concerns

OSINT: China Miner Jiang Zhuoer Forecasts BTC Bottom at $42‑44k in Late 2026

MORGAN STANLEY search volume spiked +46 pts - unusual interest

Q3-2025: EPS $0.00 vs $0.0152 estimate, -0.02 on a near-zero consensus

Q2-2026: EPS $-0.06 vs $-0.0478 estimate, -0.01 on a near-zero consensus

Q3-2015: EPS $-0.04 vs $0.0102 estimate, -0.05 on a near-zero consensus

Q4-2017: EPS $0.01 vs $-0.0408 estimate, +0.05 on a near-zero consensus

Q4-2025: EPS $-0.03 vs $-0.0408 estimate, +0.01 on a near-zero consensus

Q4-2025: EPS $-0.05 vs $0.018 estimate, -0.07 on a near-zero consensus

Q2-2024: EPS $-0.01 vs $-0.0204 estimate, +0.01 on a near-zero consensus

BTC ETF inflow of $2798M - institutional buying

ETH ETF inflow of $448M - institutional buying

BITCOIN - speculators net long (+2.5σ vs 52w mean) - contrarian bear signal

SOL open interest -71.0% - OI collapse

BTC open interest -42.7% - OI collapse

ETH open interest +214.5% - OI surge

ETH open interest +223.2% - OI surge

BTC open interest +77.4% - OI surge

SOL open interest +248.0% - OI surge

ETH open interest +233.4% - OI surge

SOL open interest +140.8% - OI surge

BTC open interest +76.3% - OI surge

SOL open interest -71.4% - OI collapse

BTC open interest -66.5% - OI collapse

ETH open interest -67.7% - OI collapse

SOL DEX volume/liquidity ratio elevated (2.00x): on-chain trade volume 2.00x liquidity

OSINT: Over Half of Bitcoin Supply Now at Unrealized Loss

OSINT: Kraken Negotiates $71M Deal for 15% Stake in Aave Group

OSINT: Bitcoin drops ~20% in June, $715M long bets wiped

ETH DEX volume/liquidity ratio elevated (0.64x): on-chain trade volume 0.64x liquidity

OSINT: Crypto market sees $1.2B liquidated in 24h, longs hit $906M

OSINT: Crypto asset slides to $1.04 as 90‑day SMA ratio hits 0.33, deepening capitulati

OSINT: Ethereum price slump sparks low sentiment but hints at near‑term upside

SOL DEX volume/liquidity ratio elevated (0.84x): on-chain trade volume 0.84x liquidity

OSINT: Nearly 38% of Bitcoin Supply Unmoved for 4+ Years Signals Strong HODL Sentiment

ETH DEX volume/liquidity ratio elevated (0.58x): on-chain trade volume 0.58x liquidity

SOL DEX volume/liquidity ratio elevated (3.15x): on-chain trade volume 3.15x liquidity

ETH DEX volume/liquidity ratio elevated (0.50x): on-chain trade volume 0.50x liquidity

SOL DEX volume/liquidity ratio elevated (2.07x): on-chain trade volume 2.07x liquidity

OSINT: Google loses two senior AI researchers to Anthropic, raising AI talent concerns

OSINT: China Miner Jiang Zhuoer Forecasts BTC Bottom at $42‑44k in Late 2026

VIX at 18.9: CAUTION territory

VIX at 18.8: CAUTION territory

VIX at 18.0: CAUTION territory

VIX at 18.6: CAUTION territory

Financial conditions loosening: NFCI at -0.52, liquidity supportive

DXY -0.30% - dollar weakness signal

OSINT: US Investor Confidence Falls to 25%, Down from 34% Last Quarter

OSINT: UK Labour Party criticised in DefenceGeek post, raising political uncertainty

OSINT: China Miner Jiang Zhuoer Forecasts BTC Bottom at $42‑44k in Late 2026